Table 2.
Results of univariate and multivariate analyses for 3-year CSS
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| p value | OR (95% CI) | p value | OR (95% CI) | |
| Gender (female vs. male) | 0.02 | 0.08 (0.01–0.67) | 0.008 | 0.04 (0.01–0.44) |
| Clinical stage (I vs. II vs. III vs. IV) | 0.002 | 1.80 (1.23–2.64) | 0.001 | 2.15 (1.34–3.44) |
| Histology (adenocarcinoma vs. SCC vs. Unknown) | 0.16 | 1.51 (0.85–2.69) | ||
| GTV volume | 0.01 | 1.01 (1.00–1.02) | ||
| PTV volume | 0.008 | 1.01 (1.0–1.01) | ||
| MD | 0.006 | 1.38 (1.10–1.73) | ||
| ED | 0.01 | 1.49 (1.10–2.01) | ||
| LCR | 0.01 | 0.94 (0.89–0.99) | 0.03 | 0.94 (0.89–1.00) |
| BEDPTVmax (≧ 105.6 vs. < 105.6) | 0.01 | 0.28 (0.11–0.74) | ||
| Fractional dose | 0.02 | 0.88 (0.79–0.98) | ||
| Duration | 0.02 | 1.07 (1.01–1.13) | ||
SCC squamous cell carcinoma, GTV gross target volume, PTV planning target volume, MD maximum diameter for the tumor, ED Equivalent diameter for the tumor, LCR lymphocyte ratio, BEDPTVmax the maximum dose in PTV recorded as BED